Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
9 studies found for:    "pseudoxanthoma elasticum"
Show Display Options
RSS Create an RSS feed from your search for:
"pseudoxanthoma elasticum"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Genetic Analysis of Patients With Pseudoxanthoma Elasticum
Conditions: Pseudoxanthoma Elasticum;   PXE
2 Completed Evolution of Visual Impairment During Pseudoxanthoma Elasticum
Condition: Pseudoxanthoma Elasticum
3 Active, not recruiting Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)
Condition: Pseudoxanthoma Elasticum
Interventions: Drug: Magnesium Oxide;   Drug: Placebo
4 Recruiting Characterization of Pseudoxanthoma Elasticum
Condition: Pseudoxanthoma Elasticum
5 Recruiting Phenotypic Expressions in a French Pseudoxanthoma-Elasticum Cohort
Condition: Pseudoxanthoma Elasticum
6 Unknown  Arterial Wall Calcium Load in Pseudoxanthoma Elasticum
Conditions: Pseudoxanthoma Elasticum;   Type 2 Diabetes;   Chronic Kidney Disease
7 Completed Functional and Structural Characterization of Arteriopathy in Pseudoxanthoma Elasticum (PXE)
Condition: Pseudoxanthoma Elasticum
8 Completed Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)
Condition: Choroidal Neovascularization
Intervention: Drug: Intravitreal injection ranibizumab
9 Completed Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
Conditions: Coats' Disease;   Idiopathic Retinal Telangiectasia;   Retinal Angiomatous Proliferation;   Polypoidal Choroidal Vasculopathy;   Pseudoxanthoma Elasticum;   Pathological Myopia;   Multi-focal Choroiditis;   Rubeosis Iridis;   Von Hippel Lindau Disease;   BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
Intervention: Drug: ranibizumab injection (0.5 mg)

Indicates status has not been verified in more than two years